Uy Ear
Stock Analyst
(2.98)
# 1,510
Out of 4,648 analysts
55
Total ratings
37.5%
Success rate
3.78%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Neutral | $18 → $16 | $5.81 | +175.39% | 2 | Jul 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $19.11 | +109.31% | 1 | May 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $145 → $179 | $123.07 | +45.45% | 5 | May 17, 2024 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $17 → $18 | $8.72 | +106.42% | 12 | May 15, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $25 → $21 | $14.62 | +43.64% | 10 | May 9, 2024 | |
| QURE uniQure | Maintains: Neutral | $7 → $6 | $5.56 | +7.91% | 3 | May 8, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $16.42 | +40.07% | 3 | Mar 8, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $116 → $140 | $120.53 | +16.15% | 10 | Feb 8, 2024 | |
| RVNC Revance Therapeutics | Maintains: Buy | $35 → $16 | $5.81 | +175.39% | 1 | Nov 22, 2023 | |
| ALKS Alkermes | Maintains: Buy | $37 → $35 | $26.59 | +31.63% | 4 | Oct 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $158.24 | -74.72% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $4.00 | +150.00% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $0.96 | +213.32% | 2 | Mar 1, 2023 |
Sage Therapeutics
Jul 19, 2024
Maintains: Neutral
Price Target: $18 → $16
Current: $5.81
Upside: +175.39%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $19.11
Upside: +109.31%
Sarepta Therapeutics
May 17, 2024
Maintains: Buy
Price Target: $145 → $179
Current: $123.07
Upside: +45.45%
Arcutis Biotherapeutics
May 15, 2024
Maintains: Buy
Price Target: $17 → $18
Current: $8.72
Upside: +106.42%
ACADIA Pharmaceuticals
May 9, 2024
Maintains: Neutral
Price Target: $25 → $21
Current: $14.62
Upside: +43.64%
uniQure
May 8, 2024
Maintains: Neutral
Price Target: $7 → $6
Current: $5.56
Upside: +7.91%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $16.42
Upside: +40.07%
Neurocrine Biosciences
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $120.53
Upside: +16.15%
Revance Therapeutics
Nov 22, 2023
Maintains: Buy
Price Target: $35 → $16
Current: $5.81
Upside: +175.39%
Alkermes
Oct 26, 2023
Maintains: Buy
Price Target: $37 → $35
Current: $26.59
Upside: +31.63%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $158.24
Upside: -74.72%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $4.00
Upside: +150.00%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $0.96
Upside: +213.32%